{"gene":"MUL1","run_date":"2026-06-10T05:19:51","timeline":{"discoveries":[{"year":2008,"finding":"MUL1/MULAN is a mitochondrial outer membrane protein with two transmembrane domains mediating its localization; its C-terminal RING finger domain is exposed to the cytosol and is required for E3 ubiquitin ligase activity. Both an intact RING finger and correct subcellular localization are required for regulation of mitochondrial dynamics.","method":"Imaging-based screen, ectopic expression, RNAi knockdown, domain mutagenesis, subcellular fractionation","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (imaging screen, KD, OE, mutagenesis) in a single focused study establishing localization and functional requirements","pmids":["18213395"],"is_preprint":false},{"year":2008,"finding":"GIDE/MUL1 induces apoptosis via a pathway requiring its RING finger E3 ligase activity, involving JNK activation upstream of cytochrome c and Smac release, and downstream caspase activation; XIAP and dominant-negative caspase-9 block GIDE-induced apoptosis.","method":"Overexpression, caspase inhibitor treatment, dominant-negative constructs, cytochrome c/Smac release assays, JNK activation assays","journal":"Cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal functional assays in single lab establishing apoptotic pathway placement","pmids":["18591963"],"is_preprint":false},{"year":2009,"finding":"MAPL/MUL1 functions as the first mitochondrial-anchored SUMO E3 ligase and directly SUMOylates DRP1, the mitochondrial fission GTPase, thereby stimulating mitochondrial fission.","method":"Biochemical SUMO conjugation assays, overexpression, RNAi, Co-IP to identify DRP1 as substrate","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro biochemical SUMO E3 assay combined with substrate identification and RNAi phenotype, single lab but multiple orthogonal methods","pmids":["19407830"],"is_preprint":false},{"year":2012,"finding":"MULAN/MUL1 activates NF-κB through a pathway dependent on mitochondrial hyperfusion; MULAN forms a complex with TRAF2 and modulates its ubiquitylation, with NF-κB activation requiring the RING domain of MULAN and being TAK1- and IKK-dependent.","method":"Expression of dominant-negative Drp1 and MARCH5 to induce hyperfusion, MULAN knockdown, NF-κB reporter assays, Co-IP of MULAN with TRAF2","journal":"The FEBS journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus reporter assay plus domain requirement, single lab","pmids":["24841215"],"is_preprint":false},{"year":2012,"finding":"MUL1 ubiquitinates and promotes degradation of the mitochondrial fusion protein Mfn2, leading to mitophagy; FoxO1/3 transcription factors regulate MUL1 expression upstream of this pathway during muscle wasting. NOTE: This paper (PMID 23140641) was subsequently retracted due to data falsification (PMID 26973995); findings should be treated with very low confidence.","method":"Overexpression, siRNA knockdown, ubiquitination assays, muscle wasting models — RETRACTED","journal":"Cell metabolism","confidence":"Low","confidence_rationale":"Tier 3 / Weak — paper was formally retracted due to falsified data; finding cannot be trusted despite initial publication","pmids":["23140641","26973995"],"is_preprint":false},{"year":2012,"finding":"MUL1 interacts with MAVS at the mitochondrial outer membrane and catalyzes post-translational modifications of RIG-I that inhibit RIG-I-dependent NF-κB and IFN-β signaling; MUL1 depletion potentiates RIG-I-mediated antiviral responses.","method":"Co-IP of MUL1 with MAVS, RIG-I modification assays, MUL1 siRNA knockdown, NF-κB/IFN-β reporter assays, Sendai virus and poly I:C challenge","journal":"Immunology and cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus functional reporter assays plus loss-of-function, single lab","pmids":["23399697"],"is_preprint":false},{"year":2012,"finding":"MULAN/MUL1 directly interacts with and ubiquitinates AKT (preferentially phosphorylated AKT), leading to proteasomal degradation of AKT and suppression of cell proliferation and viability.","method":"Co-IP of AKT with MULAN, in vitro ubiquitination assay, in vivo ubiquitination assay, RING finger domain mutagenesis, cell proliferation/viability assays","journal":"Cell research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro and in vivo ubiquitination assays plus Co-IP plus functional phenotype, multiple orthogonal methods in single lab","pmids":["22410793"],"is_preprint":false},{"year":2014,"finding":"MUL1 acts in parallel to the PINK1/Parkin pathway to ubiquitinate and degrade Mitofusin (Mfn), maintaining mitochondrial integrity; removing MUL1 in PINK1 or parkin mutant background aggravates phenotypes leading to lethality in Drosophila and neuronal degeneration in mice.","method":"Drosophila genetic epistasis (double mutants), mouse cortical neuron degeneration assays, ubiquitin-dependent degradation assays for Mitofusin","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis in Drosophila and mammalian neurons, multiple orthogonal approaches, replicated across organisms","pmids":["24898855"],"is_preprint":false},{"year":2014,"finding":"Mulan/MUL1 interacts with four specific E2 ubiquitin conjugating enzymes (Ube2E2, Ube2E3, Ube2G2, Ube2L3); the Mulan-Ube2E3 complex specifically recruits GABARAP via an LIR motif in the RING finger domain of Mulan, providing a mechanism for MUL1's role in mitophagy.","method":"Modified yeast two-hybrid screen using RING finger-E2 fusions, Co-IP, LIR motif mutagenesis","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — yeast two-hybrid plus Co-IP plus mutagenesis, single lab","pmids":["25224329"],"is_preprint":false},{"year":2014,"finding":"Omi/HtrA2 protease degrades Mulan/MUL1 as a substrate during H2O2 exposure; loss of Omi/HtrA2 protease activity leads to Mulan accumulation, decreased Mfn2 protein, and increased mitophagy in mnd2 mutant mice and Omi/HtrA2-/- MEFs.","method":"In vitro protease assay, western blot of Mulan in mnd2 mice tissues and KO MEFs, Mfn2 protein quantification, mitophagy assays","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — substrate identification via protease assay, validated in genetic mouse model tissues, single lab","pmids":["24709290"],"is_preprint":false},{"year":2015,"finding":"MUL1/MAPL-dependent SUMOylation of DRP1 is required for cytochrome c release during apoptosis; SUMOylated DRP1 stabilizes ER/mitochondrial contact sites that act as hotspots for mitochondrial constriction, calcium flux, cristae remodeling, and cytochrome c release. MAPL acts downstream of BAX/BAK activation.","method":"MAPL loss-of-function, SUMOylation assays, ER/mitochondrial contact site imaging, cytochrome c release assays, BAX/BAK assembly assays, calcium flux measurements","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Moderate — multiple orthogonal methods (SUMOylation assay, organelle contact imaging, functional cytochrome c release, epistasis with BAX/BAK), single lab but rigorous","pmids":["26384664"],"is_preprint":false},{"year":2015,"finding":"MUL1 ubiquitinates ULK1 (after ULK1 translocates to mitochondria following selenite treatment) and interacts with ULK1; MUL1 regulates selenite-induced mitophagy in an ATG5- and ULK1-dependent manner.","method":"Co-IP of ULK1 with MUL1, ubiquitination assays, ATG5/ULK1 dependency experiments, mitophagy assays","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus ubiquitination assay plus genetic dependency, single lab","pmids":["26018823"],"is_preprint":false},{"year":2016,"finding":"MUL1 and PARKIN play redundant roles in elimination of paternal mitochondria in mouse pre-implantation embryos via mitophagy; the process requires mitochondrial depolarization of paternal mitochondria, FIS1, the autophagy adaptor P62, and PINK1 kinase.","method":"Genetic knockout of PARKIN and MUL1 in mouse embryos and fibroblasts, mitophagy assays (autophagosome sequestration, lysosomal delivery), double mutant analysis","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO combined with live imaging mitophagy assays in both cell lines and pre-implantation embryos, rigorous epistasis","pmids":["27852436"],"is_preprint":false},{"year":2017,"finding":"MAPL/MUL1 is required for RIG-I SUMOylation in a Sendai virus infection context; this SUMOylation is required for RIG-I activation and drives antiviral gene transcription. MAPL was not required for signaling downstream of constitutively active RIG-I, placing it upstream of RIG-I activation.","method":"BioID proximity labeling proteomics of MAPL interactors during Sendai infection, MAPL knockout in vivo and in vitro, RIG-I SUMOylation assay, epistasis with constitutively active RIG-I","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 2 / Moderate — BioID interactome plus genetic KO plus epistasis analysis with constitutively active form, multiple orthogonal methods","pmids":["28273895"],"is_preprint":false},{"year":2017,"finding":"FOXO3 transcriptionally regulates MUL1 expression; cisplatin-induced ROS activates FOXO3, which upregulates MUL1, leading to ubiquitylation of active (phosphorylated) AKT.","method":"FOXO3 knockdown, ROS quantification, MUL1 expression analysis, AKT ubiquitylation assays","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — functional knockdown plus ubiquitination assay, single lab, limited structural validation","pmids":["29299162"],"is_preprint":false},{"year":2018,"finding":"MUL1 ubiquitinates HSPA5/GRP78 at K48-linked polyubiquitin chains at the K446 residue, leading to HSPA5 degradation; HSPA5 negatively regulates lysosomal activity and MUL1 knockdown prevents HSPA5 ubiquitination.","method":"Co-IP, ubiquitination assay (K48-linkage specificity), CRISPR/Cas9 MUL1 KO, site-directed mutagenesis of K446, in vivo xenograft model","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ubiquitination with linkage specificity, site mutagenesis, CRISPR KO validation, single lab","pmids":["29260979"],"is_preprint":false},{"year":2019,"finding":"MUL1 deficiency leads to increased Mfn2 activity, triggering mitochondrial hyperfusion as a first phase response, and acts as an ER-mitochondria tethering antagonist; reduced ER-Mito coupling increases cytoplasmic Ca2+ load, which activates calcineurin and induces DRP1-dependent mitochondrial fragmentation and Parkin-mediated mitophagy as a second phase.","method":"MUL1 KO in neurons, Ca2+ flux measurements, calcineurin inhibitor experiments, ER-Mito contact site quantification, Mfn2/Mfn1 overexpression epistasis, PTPIP51 overexpression rescue","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods including genetic KO, pharmacological inhibition, epistasis with Mfn2/PTPIP51, Ca2+ measurements, ER-Mito contact imaging","pmids":["31409786"],"is_preprint":false},{"year":2019,"finding":"The NMR solution structure of the MUL1 RING domain was determined; the RING domain adopts a ββαβ fold with a canonical cross-brace motif coordinating two zinc ions. NMR chemical shift perturbation experiments showed the RING domain interacts with the p53 transactivation domain (p53-TAD), primarily through the TAD2 subdomain (residues 39-57).","method":"NMR spectroscopy (structure determination and chemical shift perturbation), in vitro binding assays","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NMR structure with functional interaction mapping, rigorous structural biology","pmids":["31235254"],"is_preprint":false},{"year":2020,"finding":"MUL1 stabilizes PINK1 on the outer mitochondrial membrane in a Parkin-independent manner during gemcitabine treatment, inducing mitophagy without mitochondrial depolarization.","method":"MUL1 knockdown/KO, PINK1 stability assays, mitophagy assays, gemcitabine treatment in Parkin-deficient cells","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO plus PINK1 stability assays in multiple cell contexts, single lab","pmids":["32001742"],"is_preprint":false},{"year":2020,"finding":"MUL1 ubiquitinates and degrades UBXN7 (cofactor of the CRL2VHL E3 complex) via K48-linked polyubiquitination; inactivation of MUL1 leads to UBXN7 accumulation, increased HIF-1α protein levels, reduced oxidative phosphorylation, and increased glycolysis under normoxic conditions.","method":"UBXN7 identification as MUL1 substrate, K48 ubiquitination assays, MUL1 KO cells, HIF-1α protein level measurement, metabolic flux analysis","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — substrate identification with linkage-specific ubiquitination assay and functional metabolic readout, single lab","pmids":["32005965"],"is_preprint":false},{"year":2021,"finding":"MUL1 ubiquitinates ULK1 leading to its degradation; miR-135b-5p targets MUL1 mRNA to suppress MUL1 expression, thereby preventing ULK1 degradation and inducing protective autophagy that promotes oxaliplatin resistance in colorectal cancer.","method":"miRNA target validation (luciferase reporter), MUL1 overexpression/knockdown, ULK1 ubiquitination assays, autophagy assays, xenograft models","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ubiquitination assay combined with miRNA target validation and in vivo xenograft, single lab","pmids":["34140641"],"is_preprint":false},{"year":2022,"finding":"MUL1 RING domain recruits the substrate p53-TAD as a complex with UBE2D2-ubiquitin (UBE2D2~UB) conjugate; the presence of UBE2D2~UB thioester mimetic enhances TADp53 binding affinity for the RING:E2 complex, and RING-binding induces closed conformation of UBE2D2 to activate ubiquitin transfer. This mechanism underlies ubiquitylation of intrinsically disordered p53-TAD.","method":"Crystal/NMR structure of RING:UBE2D2 complex, oxyester UB mimetics, hydrolysis assays, UBE2D2 mutagenesis (N77A), binding affinity measurements","journal":"The FEBS journal","confidence":"High","confidence_rationale":"Tier 1 / Moderate — structural analysis combined with UB-mimetic functional assays and mutagenesis, rigorous mechanistic dissection","pmids":["35048531"],"is_preprint":false},{"year":2022,"finding":"MUL1 regulates mitochondrial metabolism through K48-specific polyubiquitination and degradation of both Akt2 and HIF-1α; absence of MUL1 leads to accumulation and activation of both substrates, causing a shift from oxidative phosphorylation to glycolysis and altered lipid metabolism.","method":"MUL1 KO cells, metabolomics, lipidomics, gene expression profiling, metabolic flux analysis (Seahorse), specific chemical inhibitors/activators of HIF-1α and Akt2, Akt2 KO cells","journal":"Frontiers in cell and developmental biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (metabolomics, lipidomics, flux analysis, genetic KO of substrates), single lab but highly comprehensive","pmids":["35846359"],"is_preprint":false},{"year":2023,"finding":"MAPL/MUL1 interacts with and SUMOylates the peroxisomal bile acid transporter ABCD3; MAPL loss leads to increased bile acid production and defective regulatory feedback in liver, identifying MAPL as a regulator of bile acid synthesis with cell-autonomous function in hepatocytes.","method":"MAPL KO mice (viable), BioID proximity labeling identifying ABCD3 as primary interactor, SUMO conjugation assays, bile acid measurement, primary hepatocyte isolation","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO mouse model, BioID interactome identification of primary substrate, SUMOylation assay, in vivo and cell-autonomous validation","pmids":["37962001"],"is_preprint":false},{"year":2024,"finding":"MUL1 SUMOylates HSPA9 at the K612 residue, promoting HSPA9 export from mitochondria to the nucleus where it interacts with SUZ12; nuclear HSPA9 leads to MUL1-induced ubiquitination-mediated degradation of SUZ12 and EZH2, and downstream STAT3 pathway inhibition, suppressing lymph node metastasis of bladder cancer.","method":"Co-IP, SUMO conjugation assays, site-directed mutagenesis of K612, nuclear fractionation, HSPA9 localization imaging, SUZ12/EZH2 ubiquitination assays, in vivo xenograft/metastasis models","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — SUMOylation with site mutagenesis plus Co-IP plus in vivo validation, single lab","pmids":["39113711"],"is_preprint":false},{"year":2024,"finding":"MAPL/MUL1 promotes SUMOylation of DRP1 in cardiomyocytes under septic conditions; MAPL deficiency reduces DRP1 SUMOylation, alleviates mitochondrial dysfunction (restores membrane potential, reduces ROS, increases ATP), and reduces cardiac injury in CLP sepsis model.","method":"Cardiomyocyte-specific MAPL KO mice, CLP model, SUMOylation assays, mitochondrial membrane potential measurement, ROS measurement, ATP quantification","journal":"Journal of translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — tissue-specific KO mouse model with SUMOylation assays and functional mitochondrial readouts, single lab","pmids":["39529130"],"is_preprint":false},{"year":2024,"finding":"MUL1 deficiency in oocytes increases reactive oxygen species (ROS) concentrations at the mitochondrial outer membrane, triggering a DNA damage response (DDR) and abnormal preimplantation embryogenesis; this phenotype is rescued by NAC (antioxidant) addition.","method":"Female Mul1 KO mice (infertility phenotype), ROS measurement in oocytes, DDR marker assays, NAC rescue experiments","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with phenotypic rescue, ROS and DDR assays, single lab","pmids":["38639871"],"is_preprint":false},{"year":2025,"finding":"MUL1 ubiquitinates and promotes degradation of CPT2 (carnitine palmitoyltransferase 2); SLC44A2 enhances the MUL1-CPT2 interaction (without changing MUL1 expression levels) to promote CPT2 degradation and suppress mitochondrial fatty acid oxidation in colorectal cancer.","method":"Co-IP of MUL1 with CPT2, ubiquitination assays, SLC44A2 overexpression/knockdown, fatty acid oxidation assays, in vivo tumor models","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus ubiquitination assay plus functional metabolic readout, single lab","pmids":["40592838"],"is_preprint":false},{"year":2025,"finding":"MAPL/MUL1 induces pyroptosis by promoting mitochondrial DNA (mtDNA) trafficking via mitochondria-derived vesicles (MDVs) to lysosomes, which are then permeabilized via gasdermin pores; released mtDNA activates cytosolic cGAS, triggering inflammatory cell death. VPS35 and LRRK2 (Parkinson's disease genes) regulate this pathway.","method":"Genome-wide functional genetic screen, MAPL overexpression/depletion, mtDNA trafficking assays, lysosomal permeabilization assay, cGAS knockdown epistasis, primary macrophage depletion experiments, LRRK2/VPS35 genetic interaction","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide screen plus multiple orthogonal mechanistic experiments (MDV trafficking, gasdermin requirement, cGAS epistasis) in multiple cell types including primary macrophages","pmids":["41083601"],"is_preprint":false},{"year":2025,"finding":"MAPL/MUL1 promotes SUMO-2/3 modification of PINK1, suppressing basal mitophagy; MAPL depletion reduces PINK1 SUMOylation and enhances basal mitophagy, while targeted deSUMOylation increases PINK1 stabilization and augments mitophagy.","method":"MAPL depletion, PINK1 SUMO-2/3 conjugation assays, targeted deSUMOylation, mitophagy assays","journal":"bioRxiv (preprint)","confidence":"Low","confidence_rationale":"Tier 3 / Weak — preprint, single lab, limited method detail in abstract","pmids":[],"is_preprint":true},{"year":2025,"finding":"MAPL/MUL1 SUMOylates DRP1 (via SUMO1 modification), promoting DRP1 mitochondrial translocation and mitochondrial fission in nucleus pulposus cells; mutation of SUMO-acceptor lysine residues on DRP1 blocks its SUMOylation and rescues MAPL-induced mitochondrial fragmentation. SENP5 acts as the opposing deSUMOylase.","method":"MAPL overexpression/knockdown in NPCs, SUMO1 modification assays for DRP1, DRP1 SUMO-site mutagenesis, SENP5 overexpression, AAV-mediated MAPL expression in rat IVDD model","journal":"Bone research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — DRP1 SUMOylation with site mutagenesis plus in vivo AAV model, single lab","pmids":["40796734"],"is_preprint":false},{"year":2025,"finding":"MUL1 ubiquitinates FUNDC1, reducing FUNDC1 protein stability; reduced FUNDC1 leads to decreased DRP1 expression and inhibition of DRP1-dependent mitophagy in cervical cancer cells.","method":"Co-IP, ubiquitination assay for FUNDC1, MUL1 overexpression/knockdown, mitophagy assays, DRP1 expression analysis, in vivo xenograft","journal":"Journal of molecular histology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus ubiquitination assay plus in vivo tumor model, single lab","pmids":["41697489"],"is_preprint":false}],"current_model":"MUL1/MULAN/MAPL is a dual ubiquitin and SUMO E3 ligase anchored in the mitochondrial outer membrane via two transmembrane domains, with its catalytic C-terminal RING finger domain exposed to the cytosol; it ubiquitinates substrates including AKT, Mfn1/2, ULK1, PINK1 (stabilization), UBXN7, Akt2, HIF-1α, HSPA5, FUNDC1, CPT2, and p53-TAD (via recruitment of UBE2D2~Ub conjugate), and SUMOylates DRP1, RIG-I, PINK1, ABCD3, HSPA9, and NDP52, thereby regulating mitochondrial dynamics (fission/fusion), mitophagy, ER-mitochondrial contact sites, apoptotic cytochrome c release, antiviral innate immune signaling, metabolic reprogramming, and pyroptosis through mtDNA-cGAS-gasdermin pathway activation."},"narrative":{"mechanistic_narrative":"MUL1 (MULAN/MAPL/GIDE) is a mitochondrial outer-membrane E3 ligase that governs mitochondrial dynamics, quality control, metabolism, and cell death through a single cytosol-exposed RING domain capable of both ubiquitin and SUMO conjugation [PMID:18213395, PMID:19407830]. It is anchored in the outer membrane by two transmembrane segments, and both an intact RING finger and correct localization are required for its control of mitochondrial morphology [PMID:18213395]; the RING adopts a canonical cross-brace βββαβ zinc-coordinating fold and engages substrates such as the p53 transactivation domain while recruiting E2~ubiquitin conjugates (UBE2D2~Ub) into a closed, transfer-competent conformation [PMID:31235254, PMID:35048531]. As the first mitochondria-anchored SUMO ligase, MUL1 SUMOylates the fission GTPase DRP1 to stimulate fission [PMID:19407830], and DRP1 SUMOylation stabilizes ER–mitochondrial contact sites that serve as hotspots for constriction, calcium flux, and cytochrome c release downstream of BAX/BAK during apoptosis [PMID:26384664]. In its ubiquitin-ligase capacity, MUL1 targets mitofusins to control fusion and acts in parallel to the PINK1/Parkin axis to maintain mitochondrial integrity, with combined loss producing neurodegeneration [PMID:24898855]; MUL1 and Parkin also act redundantly in mitophagic elimination of paternal mitochondria in embryos [PMID:27852436]. MUL1 ubiquitinates active AKT and HIF-1α/Akt2 via K48 chains to suppress proliferation and restrain a glycolytic metabolic shift [PMID:22410793, PMID:35846359], and its expression is driven by FOXO3 under oxidative stress [PMID:29299162]. It additionally regulates ER–mitochondria tethering and calcium homeostasis, where its loss triggers biphasic hyperfusion-then-fragmentation responses [PMID:31409786], modulates antiviral RIG-I signaling through SUMOylation [PMID:28273895], controls bile-acid synthesis by SUMOylating the peroxisomal transporter ABCD3 [PMID:37962001], and drives mtDNA–cGAS–gasdermin-dependent pyroptosis via mitochondria-derived vesicle trafficking to lysosomes [PMID:41083601]. MUL1 loss in oocytes elevates outer-membrane ROS and triggers a DNA-damage response causing infertility, rescued by antioxidant [PMID:38639871].","teleology":[{"year":2008,"claim":"Established MUL1 as a topologically defined mitochondrial outer-membrane RING E3 ligase whose activity and localization jointly control mitochondrial dynamics, defining the protein's physical platform.","evidence":"Imaging screen, fractionation, domain mutagenesis and RNAi in cells","pmids":["18213395"],"confidence":"High","gaps":["Direct ubiquitination substrates not yet identified","Mechanism linking RING activity to morphology unresolved at this stage"]},{"year":2008,"claim":"Placed MUL1 (GIDE) within an apoptotic pathway upstream of cytochrome c/Smac release and caspase-9 activation, showing RING-dependent pro-death function.","evidence":"Overexpression with dominant-negative caspase-9, XIAP, and JNK/cytochrome c release assays","pmids":["18591963"],"confidence":"Medium","gaps":["No direct ubiquitination substrate in the apoptotic pathway identified","JNK activation mechanism not defined"]},{"year":2009,"claim":"Defined MUL1 as the first mitochondria-anchored SUMO E3 ligase and identified DRP1 as a direct SUMO substrate, revealing a non-ubiquitin enzymatic mode driving fission.","evidence":"In vitro SUMO conjugation assays, Co-IP, RNAi phenotype","pmids":["19407830"],"confidence":"High","gaps":["DRP1 SUMO-acceptor residues not mapped here","Opposing deSUMOylase unidentified at this stage"]},{"year":2012,"claim":"Identified active AKT as a direct K48-ubiquitination substrate, establishing MUL1 as a negative regulator of pro-survival/proliferative signaling.","evidence":"In vitro and in vivo ubiquitination assays, Co-IP, RING mutagenesis, proliferation assays","pmids":["22410793"],"confidence":"High","gaps":["Preference for phosphorylated AKT not structurally explained","In vivo physiological relevance not established here"]},{"year":2012,"claim":"Linked MUL1 to inflammatory and antiviral signaling, showing complex formation with TRAF2/NF-κB activation and interaction with MAVS to negatively modulate RIG-I responses.","evidence":"Co-IP, NF-κB/IFN-β reporter assays, knockdown, viral challenge","pmids":["24841215","23399697"],"confidence":"Medium","gaps":["Direct vs indirect modification of RIG-I unresolved","Apparent inhibitory role conflicts with later activating SUMOylation finding"]},{"year":2014,"claim":"Demonstrated MUL1 acts in a pathway parallel to PINK1/Parkin to degrade mitofusin and preserve mitochondrial integrity, with combined loss causing degeneration.","evidence":"Drosophila genetic epistasis, mouse cortical neuron assays, mitofusin degradation assays","pmids":["24898855"],"confidence":"High","gaps":["Molecular basis of parallelism with PINK1/Parkin not detailed","Relative substrate contribution in vivo unclear"]},{"year":2014,"claim":"Mapped the E2 partners of MUL1 and an LIR motif in its RING that recruits GABARAP, providing a mechanistic link from the ligase to the autophagy machinery, and identified Omi/HtrA2 as a protease that turns MUL1 over.","evidence":"Modified yeast two-hybrid (RING-E2 fusions), Co-IP, LIR mutagenesis; in vitro protease assay in mnd2 mouse tissues","pmids":["25224329","24709290"],"confidence":"Medium","gaps":["E2 selectivity for ubiquitin vs SUMO outputs unclear","GABARAP-dependent mitophagy substrate cargo not defined"]},{"year":2015,"claim":"Connected MUL1-dependent DRP1 SUMOylation to ER–mitochondrial contact-site stabilization required for cytochrome c release, positioning MUL1 downstream of BAX/BAK in apoptosis.","evidence":"Loss-of-function, SUMOylation and contact-site imaging, calcium flux and cytochrome c release assays, BAX/BAK epistasis","pmids":["26384664"],"confidence":"High","gaps":["Structural basis of contact-site stabilization by SUMO-DRP1 not resolved","Link to upstream apoptotic triggers incomplete"]},{"year":2015,"claim":"Showed MUL1 ubiquitinates ULK1 upon its mitochondrial translocation, integrating MUL1 into ATG5/ULK1-dependent stress-induced mitophagy.","evidence":"Co-IP, ubiquitination assays, genetic dependency on ATG5/ULK1, mitophagy assays","pmids":["26018823"],"confidence":"Medium","gaps":["Ubiquitin chain type and consequence on ULK1 not defined here","Selectivity of ULK1 targeting unclear"]},{"year":2016,"claim":"Established functional redundancy between MUL1 and Parkin in developmental mitophagy, eliminating paternal mitochondria via a PINK1/FIS1/P62-dependent route.","evidence":"Genetic knockout in mouse embryos and fibroblasts, double-mutant analysis, mitophagy imaging","pmids":["27852436"],"confidence":"High","gaps":["Whether MUL1 acts via ubiquitin or SUMO output here untested","Substrate driving paternal mitochondrial clearance unidentified"]},{"year":2017,"claim":"Resolved MUL1's antiviral role as a positive one, showing MAPL-dependent RIG-I SUMOylation is required upstream of RIG-I activation for antiviral transcription.","evidence":"BioID interactome during Sendai infection, in vivo/in vitro KO, RIG-I SUMOylation assay, epistasis with constitutively active RIG-I","pmids":["28273895"],"confidence":"High","gaps":["Reconciliation with earlier inhibitory RIG-I report not addressed","RIG-I SUMO-acceptor sites not mapped"]},{"year":2019,"claim":"Determined the RING domain solution structure and mapped its direct interaction with the p53 transactivation domain, giving the first atomic view of substrate engagement.","evidence":"NMR structure determination and chemical-shift perturbation, in vitro binding","pmids":["31235254"],"confidence":"High","gaps":["Functional consequence of p53-TAD ubiquitination on p53 activity not shown","Cellular context of p53 targeting undefined"]},{"year":2019,"claim":"Defined MUL1 as an ER–mitochondria tethering antagonist whose loss drives a biphasic hyperfusion-then-calcineurin/DRP1-fragmentation/Parkin-mitophagy response, linking the ligase to calcium homeostasis.","evidence":"Neuronal KO, Ca2+ flux, calcineurin inhibition, contact-site imaging, Mfn2/PTPIP51 epistasis and rescue","pmids":["31409786"],"confidence":"High","gaps":["Direct substrate at the tether unresolved","How a single ligase produces opposing temporal phases not fully mechanistic"]},{"year":2022,"claim":"Provided the mechanistic basis for MUL1 ubiquitinating intrinsically disordered substrates, showing the RING recruits p53-TAD together with UBE2D2~Ub and induces a closed, transfer-competent E2 conformation.","evidence":"Crystal/NMR of RING:UBE2D2, ubiquitin oxyester mimetics, hydrolysis assays, UBE2D2 N77A mutagenesis, affinity measurements","pmids":["35048531"],"confidence":"High","gaps":["In-cell p53 regulation by this mechanism not demonstrated","Generalizability to other disordered substrates untested"]},{"year":2022,"claim":"Established MUL1 as a metabolic gatekeeper through K48 degradation of Akt2 and HIF-1α (and via UBXN7), restraining the shift from oxidative phosphorylation to glycolysis and lipid remodeling.","evidence":"KO cells, metabolomics/lipidomics, Seahorse flux, substrate KO and chemical modulators; UBXN7 substrate identification with K48 assays","pmids":["35846359","32005965"],"confidence":"High","gaps":["Hierarchy among Akt2/HIF-1α/UBXN7 outputs unclear","Tissue-specific metabolic relevance not fully mapped"]},{"year":2023,"claim":"Extended MUL1 substrate range beyond mitochondria, identifying SUMOylation of the peroxisomal transporter ABCD3 as a cell-autonomous regulator of hepatic bile-acid synthesis in viable KO mice.","evidence":"KO mice, BioID interactome, SUMO conjugation assays, bile-acid measurement, primary hepatocytes","pmids":["37962001"],"confidence":"High","gaps":["Mechanism by which ABCD3 SUMOylation alters transport not defined","Cross-organelle access of a mitochondrial ligase to peroxisomal substrate unexplained"]},{"year":2024,"claim":"Demonstrated MUL1 SUMOylates HSPA9 to drive its nuclear export and downstream SUZ12/EZH2 degradation, coupling MUL1 to chromatin-modifier turnover and tumor suppression; also showed DRP1 SUMOylation drives mitochondrial dysfunction in septic cardiomyocytes and ROS/DDR control in oocytes.","evidence":"SUMO assays with site mutagenesis, nuclear fractionation, ubiquitination assays, xenografts; cardiomyocyte- and germline-specific KO mice with functional readouts and NAC rescue","pmids":["39113711","39529130","38639871"],"confidence":"Medium","gaps":["How nuclear-exported HSPA9 acquires ubiquitin-targeting of SUZ12/EZH2 mechanistically unclear","Single-lab models for each disease context"]},{"year":2025,"claim":"Identified MUL1 as an inducer of pyroptosis via MDV-mediated mtDNA trafficking to lysosomes and cGAS–gasdermin activation, embedding the ligase in an inflammatory cell-death and Parkinson's-gene (VPS35/LRRK2) network.","evidence":"Genome-wide screen, MAPL gain/loss, mtDNA trafficking and lysosomal permeabilization assays, cGAS epistasis, primary macrophages","pmids":["41083601"],"confidence":"High","gaps":["Enzymatic output (ubiquitin vs SUMO) driving MDV trafficking unresolved","Direct substrate controlling mtDNA packaging unidentified"]},{"year":2025,"claim":"Expanded MUL1 mitophagy/fission control with FUNDC1 ubiquitination, CPT2 degradation (enhanced by SLC44A2) restraining fatty-acid oxidation, and DRP1 SUMO1-driven fission in nucleus pulposus cells opposed by SENP5.","evidence":"Co-IP, ubiquitination/SUMOylation assays, site mutagenesis, FAO assays, AAV in vivo models, xenografts","pmids":["41697489","40592838","40796734"],"confidence":"Medium","gaps":["Context-specific selection among many substrates unresolved","Single-lab cancer/disease models for each finding"]},{"year":null,"claim":"How MUL1 selects between ubiquitin and SUMO outputs, and which E2/E3 cofactors and signals route it to specific substrates across mitochondria, peroxisomes, and the nucleus, remains the central open question.","evidence":"Not yet addressed in the available corpus","pmids":[],"confidence":"Low","gaps":["No unifying model for ubiquitin-vs-SUMO substrate choice","Regulation of MUL1 access to non-mitochondrial substrates undefined","PINK1 SUMOylation control of basal mitophagy rests on a preprint only"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,2,6,15,19,22,23]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,2,6,17,21,22]},{"term_id":"GO:0016874","term_label":"ligase activity","supporting_discovery_ids":[0,6,15,19]},{"term_id":"GO:0031386","term_label":"protein tag activity","supporting_discovery_ids":[2,10,13,23,30]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[0,2,10,16,28]}],"pathway":[{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[7,11,12,18]},{"term_id":"R-HSA-1852241","term_label":"Organelle biogenesis and maintenance","supporting_discovery_ids":[0,2,10,16]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[1,10,28]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[19,22,23,27]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[13,28]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[6,15,19,22]}],"complexes":[],"partners":["DRP1","AKT","HIF1A","ULK1","PINK1","TRAF2","MAVS","ABCD3"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q969V5","full_name":"Mitochondrial ubiquitin ligase activator of NFKB 1","aliases":["E3 SUMO-protein ligase MUL1","E3 ubiquitin-protein ligase MUL1","Growth inhibition and death E3 ligase","Mitochondrial-anchored protein ligase","Protein Hades","Putative NF-kappa-B-activating protein 266","RING finger protein 218","RING-type E3 ubiquitin transferase NFKB 1"],"length_aa":352,"mass_kda":39.8,"function":"Exhibits weak E3 ubiquitin-protein ligase activity (PubMed:18591963, PubMed:19407830, PubMed:22410793). E3 ubiquitin ligases accept ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfer the ubiquitin to targeted substrates (PubMed:18591963, PubMed:19407830, PubMed:22410793). Can ubiquitinate AKT1 preferentially at 'Lys-284' involving 'Lys-48'-linked polyubiquitination and seems to be involved in regulation of Akt signaling by targeting phosphorylated Akt to proteasomal degradation (PubMed:22410793). Mediates polyubiquitination of cytoplasmic TP53 at 'Lys-24' which targets TP53 for proteasomal degradation, thus reducing TP53 levels in the cytoplasm and mitochondrion (PubMed:21597459). Proposed to preferentially act as a SUMO E3 ligase at physiological concentrations (PubMed:19407830). Plays a role in the control of mitochondrial morphology by promoting mitochondrial fragmentation, and influences mitochondrial localization (PubMed:18207745, PubMed:18213395, PubMed:19407830). Likely to promote mitochondrial fission through negatively regulating the mitochondrial fusion proteins MFN1 and MFN2, acting in a pathway that is parallel to the PRKN/PINK1 regulatory pathway (PubMed:24898855). May also be involved in the sumoylation of the membrane fission protein DNM1L (PubMed:18207745, PubMed:19407830). Inhibits cell growth (PubMed:18591963, PubMed:22410793). When overexpressed, activates JNK through MAP3K7/TAK1 and induces caspase-dependent apoptosis (PubMed:23399697). Involved in the modulation of innate immune defense against viruses by inhibiting RIGI-dependent antiviral response (PubMed:23399697). Can mediate RIGI sumoylation and disrupt its polyubiquitination (PubMed:23399697)","subcellular_location":"Mitochondrion outer membrane; Peroxisome","url":"https://www.uniprot.org/uniprotkb/Q969V5/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MUL1","classification":"Not Classified","n_dependent_lines":8,"n_total_lines":1208,"dependency_fraction":0.006622516556291391},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MUL1","total_profiled":1310},"omim":[{"mim_id":"621246","title":"TRAB DOMAIN-CONTAINING PROTEIN; TRABD","url":"https://www.omim.org/entry/621246"},{"mim_id":"612037","title":"MITOCHONDRIAL UBIQUITIN LIGASE ACTIVATOR OF NFKB 1; MUL1","url":"https://www.omim.org/entry/612037"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Mitochondria","reliability":"Approved"},{"location":"Cytosol","reliability":"Approved"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/MUL1"},"hgnc":{"alias_symbol":["FLJ12875","MULAN","RNF218","MAPL","GIDE"],"prev_symbol":["C1orf166"]},"alphafold":{"accession":"Q969V5","domains":[{"cath_id":"-","chopping":"45-224","consensus_level":"high","plddt":91.464,"start":45,"end":224},{"cath_id":"3.30.40.10","chopping":"295-347","consensus_level":"high","plddt":88.33,"start":295,"end":347},{"cath_id":"1.10.287","chopping":"8-41_225-289","consensus_level":"medium","plddt":91.858,"start":8,"end":289}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q969V5","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q969V5-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q969V5-F1-predicted_aligned_error_v6.png","plddt_mean":89.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MUL1","jax_strain_url":"https://www.jax.org/strain/search?query=MUL1"},"sequence":{"accession":"Q969V5","fasta_url":"https://rest.uniprot.org/uniprotkb/Q969V5.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q969V5/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q969V5"}},"corpus_meta":[{"pmid":"18213395","id":"PMC_18213395","title":"Genome-wide and functional annotation of human E3 ubiquitin ligases identifies MULAN, a mitochondrial E3 that regulates the organelle's dynamics and signaling.","date":"2008","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/18213395","citation_count":647,"is_preprint":false},{"pmid":"19407830","id":"PMC_19407830","title":"MAPL is a new mitochondrial SUMO E3 ligase that regulates mitochondrial fission.","date":"2009","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/19407830","citation_count":287,"is_preprint":false},{"pmid":"27852436","id":"PMC_27852436","title":"Elimination of paternal mitochondria in mouse embryos occurs through autophagic degradation dependent on PARKIN and MUL1.","date":"2016","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/27852436","citation_count":279,"is_preprint":false},{"pmid":"26384664","id":"PMC_26384664","title":"MAPL SUMOylation of Drp1 Stabilizes an ER/Mitochondrial Platform Required for Cell Death.","date":"2015","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/26384664","citation_count":278,"is_preprint":false},{"pmid":"24898855","id":"PMC_24898855","title":"MUL1 acts in parallel to the PINK1/parkin pathway in regulating mitofusin and compensates for loss of PINK1/parkin.","date":"2014","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/24898855","citation_count":265,"is_preprint":false},{"pmid":"15590941","id":"PMC_15590941","title":"Mulan: multiple-sequence local alignment and visualization for studying function and evolution.","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15590941","citation_count":195,"is_preprint":false},{"pmid":"26018823","id":"PMC_26018823","title":"Mitochondrial outer-membrane E3 ligase MUL1 ubiquitinates ULK1 and regulates selenite-induced mitophagy.","date":"2015","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/26018823","citation_count":130,"is_preprint":false},{"pmid":"23140641","id":"PMC_23140641","title":"The ubiquitin ligase Mul1 induces mitophagy in skeletal muscle in response to muscle-wasting stimuli.","date":"2012","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/23140641","citation_count":130,"is_preprint":false},{"pmid":"31409786","id":"PMC_31409786","title":"Mul1 restrains Parkin-mediated mitophagy in mature neurons by maintaining ER-mitochondrial contacts.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31409786","citation_count":128,"is_preprint":false},{"pmid":"22410793","id":"PMC_22410793","title":"Akt is negatively regulated by the MULAN E3 ligase.","date":"2012","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/22410793","citation_count":94,"is_preprint":false},{"pmid":"27064726","id":"PMC_27064726","title":"Melatonin rescues zebrafish embryos from the parkinsonian phenotype restoring the parkin/PINK1/DJ-1/MUL1 network.","date":"2016","source":"Journal of pineal research","url":"https://pubmed.ncbi.nlm.nih.gov/27064726","citation_count":72,"is_preprint":false},{"pmid":"25224329","id":"PMC_25224329","title":"Mulan E3 ubiquitin ligase interacts with multiple E2 conjugating enzymes and participates in mitophagy by recruiting GABARAP.","date":"2014","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/25224329","citation_count":71,"is_preprint":false},{"pmid":"29260979","id":"PMC_29260979","title":"HSPA5 negatively regulates lysosomal activity through ubiquitination of MUL1 in head and neck cancer.","date":"2018","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/29260979","citation_count":69,"is_preprint":false},{"pmid":"18591963","id":"PMC_18591963","title":"GIDE is a mitochondrial E3 ubiquitin ligase that induces apoptosis and slows growth.","date":"2008","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/18591963","citation_count":68,"is_preprint":false},{"pmid":"34140641","id":"PMC_34140641","title":"The HSF1/miR-135b-5p axis induces protective autophagy to promote oxaliplatin resistance through the MUL1/ULK1 pathway in colorectal cancer.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/34140641","citation_count":58,"is_preprint":false},{"pmid":"24709290","id":"PMC_24709290","title":"Inactivation of Omi/HtrA2 protease leads to the deregulation of mitochondrial Mulan E3 ubiquitin ligase and increased mitophagy.","date":"2014","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/24709290","citation_count":57,"is_preprint":false},{"pmid":"26450902","id":"PMC_26450902","title":"Non-thermal plasma induces AKT degradation through turn-on the MUL1 E3 ligase in head and neck cancer.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26450902","citation_count":50,"is_preprint":false},{"pmid":"24841215","id":"PMC_24841215","title":"Mitochondrial hyperfusion promotes NF-κB activation via the mitochondrial E3 ligase MULAN.","date":"2014","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/24841215","citation_count":49,"is_preprint":false},{"pmid":"32001742","id":"PMC_32001742","title":"Gemcitabine induces Parkin-independent mitophagy through mitochondrial-resident E3 ligase MUL1-mediated stabilization of PINK1.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32001742","citation_count":49,"is_preprint":false},{"pmid":"21083857","id":"PMC_21083857","title":"Molecular analysis of parasitoid linkages (MAPL): gut contents of adult parasitoid wasps reveal larval host.","date":"2010","source":"Molecular ecology","url":"https://pubmed.ncbi.nlm.nih.gov/21083857","citation_count":46,"is_preprint":false},{"pmid":"23399697","id":"PMC_23399697","title":"Mitochondrially localised MUL1 is a novel modulator of antiviral signaling.","date":"2013","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/23399697","citation_count":40,"is_preprint":false},{"pmid":"37252276","id":"PMC_37252276","title":"Ginsenoside compound K protects against cerebral ischemia/reperfusion injury via Mul1/Mfn2-mediated mitochondrial dynamics and bioenergy.","date":"2022","source":"Journal of ginseng research","url":"https://pubmed.ncbi.nlm.nih.gov/37252276","citation_count":36,"is_preprint":false},{"pmid":"37489753","id":"PMC_37489753","title":"MuLan-Methyl-multiple transformer-based language models for accurate DNA methylation prediction.","date":"2023","source":"GigaScience","url":"https://pubmed.ncbi.nlm.nih.gov/37489753","citation_count":33,"is_preprint":false},{"pmid":"31679452","id":"PMC_31679452","title":"Defending stressed mitochondria: uncovering the role of MUL1 in suppressing neuronal mitophagy.","date":"2019","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/31679452","citation_count":27,"is_preprint":false},{"pmid":"28273895","id":"PMC_28273895","title":"The dynamic interacting landscape of MAPL reveals essential functions for SUMOylation in innate immunity.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28273895","citation_count":26,"is_preprint":false},{"pmid":"32005965","id":"PMC_32005965","title":"Mitochondrial MUL1 E3 ubiquitin ligase regulates Hypoxia Inducible Factor (HIF-1α) and metabolic reprogramming by modulating the UBXN7 cofactor protein.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32005965","citation_count":25,"is_preprint":false},{"pmid":"35638168","id":"PMC_35638168","title":"Mitochondrial E3 ubiquitin ligase 1 (MUL1) as a novel therapeutic target for diseases associated with mitochondrial dysfunction.","date":"2022","source":"IUBMB life","url":"https://pubmed.ncbi.nlm.nih.gov/35638168","citation_count":24,"is_preprint":false},{"pmid":"31138137","id":"PMC_31138137","title":"Effects of MUL1 and PARKIN on the circadian clock, brain and behaviour in Drosophila Parkinson's disease models.","date":"2019","source":"BMC neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/31138137","citation_count":19,"is_preprint":false},{"pmid":"29299162","id":"PMC_29299162","title":"FOXO3 induces ubiquitylation of AKT through MUL1 regulation.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29299162","citation_count":17,"is_preprint":false},{"pmid":"35846359","id":"PMC_35846359","title":"Regulation of Metabolism by Mitochondrial MUL1 E3 Ubiquitin Ligase.","date":"2022","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/35846359","citation_count":14,"is_preprint":false},{"pmid":"30816444","id":"PMC_30816444","title":"MUL1 E3 ligase regulates the antitumor effects of metformin in chemoresistant ovarian cancer cells via AKT degradation.","date":"2019","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/30816444","citation_count":14,"is_preprint":false},{"pmid":"30716316","id":"PMC_30716316","title":"Natural compound methyl protodioscin protects rat brain from ischemia/reperfusion injury through regulation of Mul1/SOD2 pathway.","date":"2019","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30716316","citation_count":14,"is_preprint":false},{"pmid":"39113711","id":"PMC_39113711","title":"SUMO E3 ligase MUL1 inhibits lymph node metastasis of bladder cancer by mediating mitochondrial HSPA9 translocation.","date":"2024","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39113711","citation_count":13,"is_preprint":false},{"pmid":"36531208","id":"PMC_36531208","title":"Inhibition of Prostaglandin E2 Receptor EP3 Attenuates Oxidative Stress and Neuronal Apoptosis Partially by Modulating p38MAPK/FOXO3/Mul1/Mfn2 Pathway after Subarachnoid Hemorrhage in Rats.","date":"2022","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/36531208","citation_count":13,"is_preprint":false},{"pmid":"25169519","id":"PMC_25169519","title":"C13orf18 and C1orf166 (MULAN) DNA genes methylation are not associated with cervical cancer and precancerous lesions of human papillomavirus genotypes in Iranian women.","date":"2014","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/25169519","citation_count":13,"is_preprint":false},{"pmid":"37942585","id":"PMC_37942585","title":"NDP52 SUMOylation contributes to low-dose X-rays-induced cardiac hypertrophy through PINK1/Parkin-mediated mitophagy via MUL1/SUMO2 signalling.","date":"2023","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/37942585","citation_count":12,"is_preprint":false},{"pmid":"22967128","id":"PMC_22967128","title":"Innate immune genes including a mucin-like gene, mul-1, induced by ionizing radiation in Caenorhabditis elegans.","date":"2012","source":"Radiation research","url":"https://pubmed.ncbi.nlm.nih.gov/22967128","citation_count":12,"is_preprint":false},{"pmid":"41083601","id":"PMC_41083601","title":"MAPL regulates gasdermin-mediated release of mtDNA from lysosomes to drive pyroptotic cell death.","date":"2025","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/41083601","citation_count":9,"is_preprint":false},{"pmid":"35048531","id":"PMC_35048531","title":"MUL1-RING recruits the substrate, p53-TAD as a complex with UBE2D2-UB conjugate.","date":"2022","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/35048531","citation_count":9,"is_preprint":false},{"pmid":"31235254","id":"PMC_31235254","title":"Solution structure of MUL1-RING domain and its interaction with p53 transactivation domain.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/31235254","citation_count":9,"is_preprint":false},{"pmid":"23140636","id":"PMC_23140636","title":"The missing link: Mul1 signals mitophagy and muscle wasting.","date":"2012","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/23140636","citation_count":8,"is_preprint":false},{"pmid":"39529130","id":"PMC_39529130","title":"Deletion of MAPL ameliorates septic cardiomyopathy by mitigating mitochondrial dysfunction.","date":"2024","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39529130","citation_count":7,"is_preprint":false},{"pmid":"33116527","id":"PMC_33116527","title":"NR4A2 Exacerbates Cerebral Ischemic Brain Injury via Modulating microRNA-652/Mul1 Pathway.","date":"2020","source":"Neuropsychiatric disease and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/33116527","citation_count":7,"is_preprint":false},{"pmid":"36260939","id":"PMC_36260939","title":"Influence of melatonin associated with the Bio-Gide® membrane on osteoblast activity: an in vitro Study.","date":"2022","source":"Acta odontologica latinoamericana : AOL","url":"https://pubmed.ncbi.nlm.nih.gov/36260939","citation_count":7,"is_preprint":false},{"pmid":"40796734","id":"PMC_40796734","title":"The mitochondrial E3 ligase MAPL SUMOylates Drp1 to facilitate mitochondrial fission in intervertebral disc degeneration.","date":"2025","source":"Bone research","url":"https://pubmed.ncbi.nlm.nih.gov/40796734","citation_count":6,"is_preprint":false},{"pmid":"37962001","id":"PMC_37962001","title":"MAPL loss dysregulates bile and liver metabolism in mice.","date":"2023","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/37962001","citation_count":6,"is_preprint":false},{"pmid":"30793286","id":"PMC_30793286","title":"MUL1 gene polymorphisms and Parkinson's disease risk.","date":"2019","source":"Acta neurologica Scandinavica","url":"https://pubmed.ncbi.nlm.nih.gov/30793286","citation_count":5,"is_preprint":false},{"pmid":"26047467","id":"PMC_26047467","title":"The Evolutionary History of MAPL (Mitochondria-Associated Protein Ligase) and Other Eukaryotic BAM/GIDE Domain Proteins.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26047467","citation_count":5,"is_preprint":false},{"pmid":"40592838","id":"PMC_40592838","title":"SLC44A2 negatively regulates mitochondrial fatty acid oxidation to suppress colorectal progression by blocking the MUL1-CPT2 interaction.","date":"2025","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/40592838","citation_count":5,"is_preprint":false},{"pmid":"22056942","id":"PMC_22056942","title":"Cloning and expression analysis of the mitochondrial ubiquitin ligase activator of NF-κB (MULAN) in Atlantic salmon (Salmo salar).","date":"2011","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22056942","citation_count":5,"is_preprint":false},{"pmid":"38725872","id":"PMC_38725872","title":"Inactivation of mitochondrial MUL1 E3 ubiquitin ligase deregulates mitophagy and prevents diet-induced obesity in mice.","date":"2024","source":"Frontiers in molecular biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/38725872","citation_count":5,"is_preprint":false},{"pmid":"37051468","id":"PMC_37051468","title":"Myristate induces mitochondrial fragmentation and cardiomyocyte hypertrophy through mitochondrial E3 ubiquitin ligase MUL1.","date":"2023","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/37051468","citation_count":5,"is_preprint":false},{"pmid":"22989998","id":"PMC_22989998","title":"MULAN related gene (MRG): a potential novel ubiquitin ligase activator of NF-kB involved in immune response in Atlantic salmon (Salmo salar).","date":"2012","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22989998","citation_count":5,"is_preprint":false},{"pmid":"19578480","id":"PMC_19578480","title":"MICROPATTERNING OF GOLD SUBSTRATES BASED ON POLY(PROPYLENE SULFIDE-BL-ETHYLENE GLYCOL), (PPS-PEG) BACKGROUND PASSIVATION AND THE MOLECULAR-ASSEMBLY PATTERNING BY LIFT-OFF (MAPL) TECHNIQUE.","date":"2008","source":"Surface science","url":"https://pubmed.ncbi.nlm.nih.gov/19578480","citation_count":4,"is_preprint":false},{"pmid":"40989496","id":"PMC_40989496","title":"MULAN: multimodal protein language model for sequence and structure encoding.","date":"2025","source":"Bioinformatics advances","url":"https://pubmed.ncbi.nlm.nih.gov/40989496","citation_count":2,"is_preprint":false},{"pmid":"39134101","id":"PMC_39134101","title":"MUL1 identified as mitochondria-linked biomarker promoting cisplatin resistance in OC cells.","date":"2024","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/39134101","citation_count":2,"is_preprint":false},{"pmid":"38639871","id":"PMC_38639871","title":"Increased ROS levels in mitochondrial outer membrane protein Mul1-deficient oocytes result in abnormal preimplantation embryogenesis.","date":"2024","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/38639871","citation_count":1,"is_preprint":false},{"pmid":"26973995","id":"PMC_26973995","title":"Retraction Notice to: The Ubiquitin Ligase Mul1 Induces Mitophagy in Skeletal Muscle in Response to Muscle-Wasting Stimuli.","date":"2015","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/26973995","citation_count":1,"is_preprint":false},{"pmid":"41468924","id":"PMC_41468924","title":"The tumor suppressor role of mitochondrial E3 ubiquitin ligase MUL1 in osteosarcoma.","date":"2025","source":"Biochimica et biophysica acta. Molecular cell research","url":"https://pubmed.ncbi.nlm.nih.gov/41468924","citation_count":0,"is_preprint":false},{"pmid":"41697489","id":"PMC_41697489","title":"MUL1 suppresses cervical cancer progression by targeting FUNDC1 for ubiquitination and inhibiting DRP1-dependent mitophagy.","date":"2026","source":"Journal of molecular histology","url":"https://pubmed.ncbi.nlm.nih.gov/41697489","citation_count":0,"is_preprint":false},{"pmid":"41998635","id":"PMC_41998635","title":"18-β-glycyrrhetinic acid facilitates nuclear-mitochondrial communications to alleviate oxidative stress through HMGB1-cGAS-Mul1 axis in tendinopathy.","date":"2026","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41998635","citation_count":0,"is_preprint":false},{"pmid":"41944736","id":"PMC_41944736","title":"Glypican-3 Upregulated by YTHDF1 in an m6A-Dependent Manner Interacts With MUL1 to Repress HSF1 Ubiquitination Degradation, Boost CD276 Transcription, and Mediate Immune Escape in Gastric Cancer.","date":"2026","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/41944736","citation_count":0,"is_preprint":false},{"pmid":"42173292","id":"PMC_42173292","title":"Multiple ShKT domain-containing MUL-1 proteins act as redox-responsive modulators of oxidative stress signaling in C. elegans.","date":"2026","source":"Molecules and cells","url":"https://pubmed.ncbi.nlm.nih.gov/42173292","citation_count":0,"is_preprint":false},{"pmid":"38088487","id":"PMC_38088487","title":"Retraction: Protective effect of hsa-miR-570-3p targeting CD274 on triple negative breast cancer by blocking PI3K/AKT/mTOR signaling pathway. Li-Li Wang, Wei-Wei Huang, Jing Huang, Rong-Fang Huang, Na-Ni Li, Yi Hong, Mu-Lan Chen, Fan Wu, Jian Liu, Kaohsiung J Med Sci. 2020; 36(8): 581-591 (https://doi.org/10.1002/kjm2.12212).","date":"2023","source":"The Kaohsiung journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38088487","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.08.24.609515","title":"MuLAN: Mutation-driven Light Attention Networks for investigating protein-protein interactions from sequences","date":"2024-08-26","source":"bioRxiv","url":"https://doi.org/10.1101/2024.08.24.609515","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.05.27.656300","title":"SUMO-2/3 modification of PINK1 restrains basal mitophagy through MAPL-dependent regulation of mitochondrial surveillance","date":"2025-05-29","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.27.656300","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":32869,"output_tokens":7885,"usd":0.108441,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17198,"output_tokens":6283,"usd":0.121533,"stage2_stop_reason":"end_turn"},"total_usd":0.229974,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2008,\n      \"finding\": \"MUL1/MULAN is a mitochondrial outer membrane protein with two transmembrane domains mediating its localization; its C-terminal RING finger domain is exposed to the cytosol and is required for E3 ubiquitin ligase activity. Both an intact RING finger and correct subcellular localization are required for regulation of mitochondrial dynamics.\",\n      \"method\": \"Imaging-based screen, ectopic expression, RNAi knockdown, domain mutagenesis, subcellular fractionation\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (imaging screen, KD, OE, mutagenesis) in a single focused study establishing localization and functional requirements\",\n      \"pmids\": [\"18213395\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"GIDE/MUL1 induces apoptosis via a pathway requiring its RING finger E3 ligase activity, involving JNK activation upstream of cytochrome c and Smac release, and downstream caspase activation; XIAP and dominant-negative caspase-9 block GIDE-induced apoptosis.\",\n      \"method\": \"Overexpression, caspase inhibitor treatment, dominant-negative constructs, cytochrome c/Smac release assays, JNK activation assays\",\n      \"journal\": \"Cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal functional assays in single lab establishing apoptotic pathway placement\",\n      \"pmids\": [\"18591963\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"MAPL/MUL1 functions as the first mitochondrial-anchored SUMO E3 ligase and directly SUMOylates DRP1, the mitochondrial fission GTPase, thereby stimulating mitochondrial fission.\",\n      \"method\": \"Biochemical SUMO conjugation assays, overexpression, RNAi, Co-IP to identify DRP1 as substrate\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro biochemical SUMO E3 assay combined with substrate identification and RNAi phenotype, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"19407830\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"MULAN/MUL1 activates NF-κB through a pathway dependent on mitochondrial hyperfusion; MULAN forms a complex with TRAF2 and modulates its ubiquitylation, with NF-κB activation requiring the RING domain of MULAN and being TAK1- and IKK-dependent.\",\n      \"method\": \"Expression of dominant-negative Drp1 and MARCH5 to induce hyperfusion, MULAN knockdown, NF-κB reporter assays, Co-IP of MULAN with TRAF2\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus reporter assay plus domain requirement, single lab\",\n      \"pmids\": [\"24841215\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"MUL1 ubiquitinates and promotes degradation of the mitochondrial fusion protein Mfn2, leading to mitophagy; FoxO1/3 transcription factors regulate MUL1 expression upstream of this pathway during muscle wasting. NOTE: This paper (PMID 23140641) was subsequently retracted due to data falsification (PMID 26973995); findings should be treated with very low confidence.\",\n      \"method\": \"Overexpression, siRNA knockdown, ubiquitination assays, muscle wasting models — RETRACTED\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — paper was formally retracted due to falsified data; finding cannot be trusted despite initial publication\",\n      \"pmids\": [\"23140641\", \"26973995\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"MUL1 interacts with MAVS at the mitochondrial outer membrane and catalyzes post-translational modifications of RIG-I that inhibit RIG-I-dependent NF-κB and IFN-β signaling; MUL1 depletion potentiates RIG-I-mediated antiviral responses.\",\n      \"method\": \"Co-IP of MUL1 with MAVS, RIG-I modification assays, MUL1 siRNA knockdown, NF-κB/IFN-β reporter assays, Sendai virus and poly I:C challenge\",\n      \"journal\": \"Immunology and cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus functional reporter assays plus loss-of-function, single lab\",\n      \"pmids\": [\"23399697\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"MULAN/MUL1 directly interacts with and ubiquitinates AKT (preferentially phosphorylated AKT), leading to proteasomal degradation of AKT and suppression of cell proliferation and viability.\",\n      \"method\": \"Co-IP of AKT with MULAN, in vitro ubiquitination assay, in vivo ubiquitination assay, RING finger domain mutagenesis, cell proliferation/viability assays\",\n      \"journal\": \"Cell research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro and in vivo ubiquitination assays plus Co-IP plus functional phenotype, multiple orthogonal methods in single lab\",\n      \"pmids\": [\"22410793\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"MUL1 acts in parallel to the PINK1/Parkin pathway to ubiquitinate and degrade Mitofusin (Mfn), maintaining mitochondrial integrity; removing MUL1 in PINK1 or parkin mutant background aggravates phenotypes leading to lethality in Drosophila and neuronal degeneration in mice.\",\n      \"method\": \"Drosophila genetic epistasis (double mutants), mouse cortical neuron degeneration assays, ubiquitin-dependent degradation assays for Mitofusin\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis in Drosophila and mammalian neurons, multiple orthogonal approaches, replicated across organisms\",\n      \"pmids\": [\"24898855\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Mulan/MUL1 interacts with four specific E2 ubiquitin conjugating enzymes (Ube2E2, Ube2E3, Ube2G2, Ube2L3); the Mulan-Ube2E3 complex specifically recruits GABARAP via an LIR motif in the RING finger domain of Mulan, providing a mechanism for MUL1's role in mitophagy.\",\n      \"method\": \"Modified yeast two-hybrid screen using RING finger-E2 fusions, Co-IP, LIR motif mutagenesis\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast two-hybrid plus Co-IP plus mutagenesis, single lab\",\n      \"pmids\": [\"25224329\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Omi/HtrA2 protease degrades Mulan/MUL1 as a substrate during H2O2 exposure; loss of Omi/HtrA2 protease activity leads to Mulan accumulation, decreased Mfn2 protein, and increased mitophagy in mnd2 mutant mice and Omi/HtrA2-/- MEFs.\",\n      \"method\": \"In vitro protease assay, western blot of Mulan in mnd2 mice tissues and KO MEFs, Mfn2 protein quantification, mitophagy assays\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — substrate identification via protease assay, validated in genetic mouse model tissues, single lab\",\n      \"pmids\": [\"24709290\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"MUL1/MAPL-dependent SUMOylation of DRP1 is required for cytochrome c release during apoptosis; SUMOylated DRP1 stabilizes ER/mitochondrial contact sites that act as hotspots for mitochondrial constriction, calcium flux, cristae remodeling, and cytochrome c release. MAPL acts downstream of BAX/BAK activation.\",\n      \"method\": \"MAPL loss-of-function, SUMOylation assays, ER/mitochondrial contact site imaging, cytochrome c release assays, BAX/BAK assembly assays, calcium flux measurements\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple orthogonal methods (SUMOylation assay, organelle contact imaging, functional cytochrome c release, epistasis with BAX/BAK), single lab but rigorous\",\n      \"pmids\": [\"26384664\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"MUL1 ubiquitinates ULK1 (after ULK1 translocates to mitochondria following selenite treatment) and interacts with ULK1; MUL1 regulates selenite-induced mitophagy in an ATG5- and ULK1-dependent manner.\",\n      \"method\": \"Co-IP of ULK1 with MUL1, ubiquitination assays, ATG5/ULK1 dependency experiments, mitophagy assays\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus ubiquitination assay plus genetic dependency, single lab\",\n      \"pmids\": [\"26018823\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"MUL1 and PARKIN play redundant roles in elimination of paternal mitochondria in mouse pre-implantation embryos via mitophagy; the process requires mitochondrial depolarization of paternal mitochondria, FIS1, the autophagy adaptor P62, and PINK1 kinase.\",\n      \"method\": \"Genetic knockout of PARKIN and MUL1 in mouse embryos and fibroblasts, mitophagy assays (autophagosome sequestration, lysosomal delivery), double mutant analysis\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO combined with live imaging mitophagy assays in both cell lines and pre-implantation embryos, rigorous epistasis\",\n      \"pmids\": [\"27852436\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"MAPL/MUL1 is required for RIG-I SUMOylation in a Sendai virus infection context; this SUMOylation is required for RIG-I activation and drives antiviral gene transcription. MAPL was not required for signaling downstream of constitutively active RIG-I, placing it upstream of RIG-I activation.\",\n      \"method\": \"BioID proximity labeling proteomics of MAPL interactors during Sendai infection, MAPL knockout in vivo and in vitro, RIG-I SUMOylation assay, epistasis with constitutively active RIG-I\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — BioID interactome plus genetic KO plus epistasis analysis with constitutively active form, multiple orthogonal methods\",\n      \"pmids\": [\"28273895\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FOXO3 transcriptionally regulates MUL1 expression; cisplatin-induced ROS activates FOXO3, which upregulates MUL1, leading to ubiquitylation of active (phosphorylated) AKT.\",\n      \"method\": \"FOXO3 knockdown, ROS quantification, MUL1 expression analysis, AKT ubiquitylation assays\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — functional knockdown plus ubiquitination assay, single lab, limited structural validation\",\n      \"pmids\": [\"29299162\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"MUL1 ubiquitinates HSPA5/GRP78 at K48-linked polyubiquitin chains at the K446 residue, leading to HSPA5 degradation; HSPA5 negatively regulates lysosomal activity and MUL1 knockdown prevents HSPA5 ubiquitination.\",\n      \"method\": \"Co-IP, ubiquitination assay (K48-linkage specificity), CRISPR/Cas9 MUL1 KO, site-directed mutagenesis of K446, in vivo xenograft model\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ubiquitination with linkage specificity, site mutagenesis, CRISPR KO validation, single lab\",\n      \"pmids\": [\"29260979\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"MUL1 deficiency leads to increased Mfn2 activity, triggering mitochondrial hyperfusion as a first phase response, and acts as an ER-mitochondria tethering antagonist; reduced ER-Mito coupling increases cytoplasmic Ca2+ load, which activates calcineurin and induces DRP1-dependent mitochondrial fragmentation and Parkin-mediated mitophagy as a second phase.\",\n      \"method\": \"MUL1 KO in neurons, Ca2+ flux measurements, calcineurin inhibitor experiments, ER-Mito contact site quantification, Mfn2/Mfn1 overexpression epistasis, PTPIP51 overexpression rescue\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods including genetic KO, pharmacological inhibition, epistasis with Mfn2/PTPIP51, Ca2+ measurements, ER-Mito contact imaging\",\n      \"pmids\": [\"31409786\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"The NMR solution structure of the MUL1 RING domain was determined; the RING domain adopts a ββαβ fold with a canonical cross-brace motif coordinating two zinc ions. NMR chemical shift perturbation experiments showed the RING domain interacts with the p53 transactivation domain (p53-TAD), primarily through the TAD2 subdomain (residues 39-57).\",\n      \"method\": \"NMR spectroscopy (structure determination and chemical shift perturbation), in vitro binding assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR structure with functional interaction mapping, rigorous structural biology\",\n      \"pmids\": [\"31235254\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"MUL1 stabilizes PINK1 on the outer mitochondrial membrane in a Parkin-independent manner during gemcitabine treatment, inducing mitophagy without mitochondrial depolarization.\",\n      \"method\": \"MUL1 knockdown/KO, PINK1 stability assays, mitophagy assays, gemcitabine treatment in Parkin-deficient cells\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO plus PINK1 stability assays in multiple cell contexts, single lab\",\n      \"pmids\": [\"32001742\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"MUL1 ubiquitinates and degrades UBXN7 (cofactor of the CRL2VHL E3 complex) via K48-linked polyubiquitination; inactivation of MUL1 leads to UBXN7 accumulation, increased HIF-1α protein levels, reduced oxidative phosphorylation, and increased glycolysis under normoxic conditions.\",\n      \"method\": \"UBXN7 identification as MUL1 substrate, K48 ubiquitination assays, MUL1 KO cells, HIF-1α protein level measurement, metabolic flux analysis\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — substrate identification with linkage-specific ubiquitination assay and functional metabolic readout, single lab\",\n      \"pmids\": [\"32005965\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"MUL1 ubiquitinates ULK1 leading to its degradation; miR-135b-5p targets MUL1 mRNA to suppress MUL1 expression, thereby preventing ULK1 degradation and inducing protective autophagy that promotes oxaliplatin resistance in colorectal cancer.\",\n      \"method\": \"miRNA target validation (luciferase reporter), MUL1 overexpression/knockdown, ULK1 ubiquitination assays, autophagy assays, xenograft models\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ubiquitination assay combined with miRNA target validation and in vivo xenograft, single lab\",\n      \"pmids\": [\"34140641\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"MUL1 RING domain recruits the substrate p53-TAD as a complex with UBE2D2-ubiquitin (UBE2D2~UB) conjugate; the presence of UBE2D2~UB thioester mimetic enhances TADp53 binding affinity for the RING:E2 complex, and RING-binding induces closed conformation of UBE2D2 to activate ubiquitin transfer. This mechanism underlies ubiquitylation of intrinsically disordered p53-TAD.\",\n      \"method\": \"Crystal/NMR structure of RING:UBE2D2 complex, oxyester UB mimetics, hydrolysis assays, UBE2D2 mutagenesis (N77A), binding affinity measurements\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — structural analysis combined with UB-mimetic functional assays and mutagenesis, rigorous mechanistic dissection\",\n      \"pmids\": [\"35048531\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"MUL1 regulates mitochondrial metabolism through K48-specific polyubiquitination and degradation of both Akt2 and HIF-1α; absence of MUL1 leads to accumulation and activation of both substrates, causing a shift from oxidative phosphorylation to glycolysis and altered lipid metabolism.\",\n      \"method\": \"MUL1 KO cells, metabolomics, lipidomics, gene expression profiling, metabolic flux analysis (Seahorse), specific chemical inhibitors/activators of HIF-1α and Akt2, Akt2 KO cells\",\n      \"journal\": \"Frontiers in cell and developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (metabolomics, lipidomics, flux analysis, genetic KO of substrates), single lab but highly comprehensive\",\n      \"pmids\": [\"35846359\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"MAPL/MUL1 interacts with and SUMOylates the peroxisomal bile acid transporter ABCD3; MAPL loss leads to increased bile acid production and defective regulatory feedback in liver, identifying MAPL as a regulator of bile acid synthesis with cell-autonomous function in hepatocytes.\",\n      \"method\": \"MAPL KO mice (viable), BioID proximity labeling identifying ABCD3 as primary interactor, SUMO conjugation assays, bile acid measurement, primary hepatocyte isolation\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO mouse model, BioID interactome identification of primary substrate, SUMOylation assay, in vivo and cell-autonomous validation\",\n      \"pmids\": [\"37962001\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"MUL1 SUMOylates HSPA9 at the K612 residue, promoting HSPA9 export from mitochondria to the nucleus where it interacts with SUZ12; nuclear HSPA9 leads to MUL1-induced ubiquitination-mediated degradation of SUZ12 and EZH2, and downstream STAT3 pathway inhibition, suppressing lymph node metastasis of bladder cancer.\",\n      \"method\": \"Co-IP, SUMO conjugation assays, site-directed mutagenesis of K612, nuclear fractionation, HSPA9 localization imaging, SUZ12/EZH2 ubiquitination assays, in vivo xenograft/metastasis models\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — SUMOylation with site mutagenesis plus Co-IP plus in vivo validation, single lab\",\n      \"pmids\": [\"39113711\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"MAPL/MUL1 promotes SUMOylation of DRP1 in cardiomyocytes under septic conditions; MAPL deficiency reduces DRP1 SUMOylation, alleviates mitochondrial dysfunction (restores membrane potential, reduces ROS, increases ATP), and reduces cardiac injury in CLP sepsis model.\",\n      \"method\": \"Cardiomyocyte-specific MAPL KO mice, CLP model, SUMOylation assays, mitochondrial membrane potential measurement, ROS measurement, ATP quantification\",\n      \"journal\": \"Journal of translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — tissue-specific KO mouse model with SUMOylation assays and functional mitochondrial readouts, single lab\",\n      \"pmids\": [\"39529130\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"MUL1 deficiency in oocytes increases reactive oxygen species (ROS) concentrations at the mitochondrial outer membrane, triggering a DNA damage response (DDR) and abnormal preimplantation embryogenesis; this phenotype is rescued by NAC (antioxidant) addition.\",\n      \"method\": \"Female Mul1 KO mice (infertility phenotype), ROS measurement in oocytes, DDR marker assays, NAC rescue experiments\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with phenotypic rescue, ROS and DDR assays, single lab\",\n      \"pmids\": [\"38639871\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"MUL1 ubiquitinates and promotes degradation of CPT2 (carnitine palmitoyltransferase 2); SLC44A2 enhances the MUL1-CPT2 interaction (without changing MUL1 expression levels) to promote CPT2 degradation and suppress mitochondrial fatty acid oxidation in colorectal cancer.\",\n      \"method\": \"Co-IP of MUL1 with CPT2, ubiquitination assays, SLC44A2 overexpression/knockdown, fatty acid oxidation assays, in vivo tumor models\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus ubiquitination assay plus functional metabolic readout, single lab\",\n      \"pmids\": [\"40592838\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"MAPL/MUL1 induces pyroptosis by promoting mitochondrial DNA (mtDNA) trafficking via mitochondria-derived vesicles (MDVs) to lysosomes, which are then permeabilized via gasdermin pores; released mtDNA activates cytosolic cGAS, triggering inflammatory cell death. VPS35 and LRRK2 (Parkinson's disease genes) regulate this pathway.\",\n      \"method\": \"Genome-wide functional genetic screen, MAPL overexpression/depletion, mtDNA trafficking assays, lysosomal permeabilization assay, cGAS knockdown epistasis, primary macrophage depletion experiments, LRRK2/VPS35 genetic interaction\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide screen plus multiple orthogonal mechanistic experiments (MDV trafficking, gasdermin requirement, cGAS epistasis) in multiple cell types including primary macrophages\",\n      \"pmids\": [\"41083601\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"MAPL/MUL1 promotes SUMO-2/3 modification of PINK1, suppressing basal mitophagy; MAPL depletion reduces PINK1 SUMOylation and enhances basal mitophagy, while targeted deSUMOylation increases PINK1 stabilization and augments mitophagy.\",\n      \"method\": \"MAPL depletion, PINK1 SUMO-2/3 conjugation assays, targeted deSUMOylation, mitophagy assays\",\n      \"journal\": \"bioRxiv (preprint)\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — preprint, single lab, limited method detail in abstract\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"MAPL/MUL1 SUMOylates DRP1 (via SUMO1 modification), promoting DRP1 mitochondrial translocation and mitochondrial fission in nucleus pulposus cells; mutation of SUMO-acceptor lysine residues on DRP1 blocks its SUMOylation and rescues MAPL-induced mitochondrial fragmentation. SENP5 acts as the opposing deSUMOylase.\",\n      \"method\": \"MAPL overexpression/knockdown in NPCs, SUMO1 modification assays for DRP1, DRP1 SUMO-site mutagenesis, SENP5 overexpression, AAV-mediated MAPL expression in rat IVDD model\",\n      \"journal\": \"Bone research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — DRP1 SUMOylation with site mutagenesis plus in vivo AAV model, single lab\",\n      \"pmids\": [\"40796734\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"MUL1 ubiquitinates FUNDC1, reducing FUNDC1 protein stability; reduced FUNDC1 leads to decreased DRP1 expression and inhibition of DRP1-dependent mitophagy in cervical cancer cells.\",\n      \"method\": \"Co-IP, ubiquitination assay for FUNDC1, MUL1 overexpression/knockdown, mitophagy assays, DRP1 expression analysis, in vivo xenograft\",\n      \"journal\": \"Journal of molecular histology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus ubiquitination assay plus in vivo tumor model, single lab\",\n      \"pmids\": [\"41697489\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MUL1/MULAN/MAPL is a dual ubiquitin and SUMO E3 ligase anchored in the mitochondrial outer membrane via two transmembrane domains, with its catalytic C-terminal RING finger domain exposed to the cytosol; it ubiquitinates substrates including AKT, Mfn1/2, ULK1, PINK1 (stabilization), UBXN7, Akt2, HIF-1α, HSPA5, FUNDC1, CPT2, and p53-TAD (via recruitment of UBE2D2~Ub conjugate), and SUMOylates DRP1, RIG-I, PINK1, ABCD3, HSPA9, and NDP52, thereby regulating mitochondrial dynamics (fission/fusion), mitophagy, ER-mitochondrial contact sites, apoptotic cytochrome c release, antiviral innate immune signaling, metabolic reprogramming, and pyroptosis through mtDNA-cGAS-gasdermin pathway activation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"MUL1 (MULAN/MAPL/GIDE) is a mitochondrial outer-membrane E3 ligase that governs mitochondrial dynamics, quality control, metabolism, and cell death through a single cytosol-exposed RING domain capable of both ubiquitin and SUMO conjugation [#0, #2]. It is anchored in the outer membrane by two transmembrane segments, and both an intact RING finger and correct localization are required for its control of mitochondrial morphology [#0]; the RING adopts a canonical cross-brace βββαβ zinc-coordinating fold and engages substrates such as the p53 transactivation domain while recruiting E2~ubiquitin conjugates (UBE2D2~Ub) into a closed, transfer-competent conformation [#17, #21]. As the first mitochondria-anchored SUMO ligase, MUL1 SUMOylates the fission GTPase DRP1 to stimulate fission [#2], and DRP1 SUMOylation stabilizes ER–mitochondrial contact sites that serve as hotspots for constriction, calcium flux, and cytochrome c release downstream of BAX/BAK during apoptosis [#10]. In its ubiquitin-ligase capacity, MUL1 targets mitofusins to control fusion and acts in parallel to the PINK1/Parkin axis to maintain mitochondrial integrity, with combined loss producing neurodegeneration [#7]; MUL1 and Parkin also act redundantly in mitophagic elimination of paternal mitochondria in embryos [#12]. MUL1 ubiquitinates active AKT and HIF-1α/Akt2 via K48 chains to suppress proliferation and restrain a glycolytic metabolic shift [#6, #22], and its expression is driven by FOXO3 under oxidative stress [#14]. It additionally regulates ER–mitochondria tethering and calcium homeostasis, where its loss triggers biphasic hyperfusion-then-fragmentation responses [#16], modulates antiviral RIG-I signaling through SUMOylation [#13], controls bile-acid synthesis by SUMOylating the peroxisomal transporter ABCD3 [#23], and drives mtDNA–cGAS–gasdermin-dependent pyroptosis via mitochondria-derived vesicle trafficking to lysosomes [#28]. MUL1 loss in oocytes elevates outer-membrane ROS and triggers a DNA-damage response causing infertility, rescued by antioxidant [#26].\",\n  \"teleology\": [\n    {\n      \"year\": 2008,\n      \"claim\": \"Established MUL1 as a topologically defined mitochondrial outer-membrane RING E3 ligase whose activity and localization jointly control mitochondrial dynamics, defining the protein's physical platform.\",\n      \"evidence\": \"Imaging screen, fractionation, domain mutagenesis and RNAi in cells\",\n      \"pmids\": [\"18213395\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct ubiquitination substrates not yet identified\", \"Mechanism linking RING activity to morphology unresolved at this stage\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Placed MUL1 (GIDE) within an apoptotic pathway upstream of cytochrome c/Smac release and caspase-9 activation, showing RING-dependent pro-death function.\",\n      \"evidence\": \"Overexpression with dominant-negative caspase-9, XIAP, and JNK/cytochrome c release assays\",\n      \"pmids\": [\"18591963\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No direct ubiquitination substrate in the apoptotic pathway identified\", \"JNK activation mechanism not defined\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined MUL1 as the first mitochondria-anchored SUMO E3 ligase and identified DRP1 as a direct SUMO substrate, revealing a non-ubiquitin enzymatic mode driving fission.\",\n      \"evidence\": \"In vitro SUMO conjugation assays, Co-IP, RNAi phenotype\",\n      \"pmids\": [\"19407830\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"DRP1 SUMO-acceptor residues not mapped here\", \"Opposing deSUMOylase unidentified at this stage\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identified active AKT as a direct K48-ubiquitination substrate, establishing MUL1 as a negative regulator of pro-survival/proliferative signaling.\",\n      \"evidence\": \"In vitro and in vivo ubiquitination assays, Co-IP, RING mutagenesis, proliferation assays\",\n      \"pmids\": [\"22410793\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Preference for phosphorylated AKT not structurally explained\", \"In vivo physiological relevance not established here\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Linked MUL1 to inflammatory and antiviral signaling, showing complex formation with TRAF2/NF-κB activation and interaction with MAVS to negatively modulate RIG-I responses.\",\n      \"evidence\": \"Co-IP, NF-κB/IFN-β reporter assays, knockdown, viral challenge\",\n      \"pmids\": [\"24841215\", \"23399697\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect modification of RIG-I unresolved\", \"Apparent inhibitory role conflicts with later activating SUMOylation finding\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrated MUL1 acts in a pathway parallel to PINK1/Parkin to degrade mitofusin and preserve mitochondrial integrity, with combined loss causing degeneration.\",\n      \"evidence\": \"Drosophila genetic epistasis, mouse cortical neuron assays, mitofusin degradation assays\",\n      \"pmids\": [\"24898855\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of parallelism with PINK1/Parkin not detailed\", \"Relative substrate contribution in vivo unclear\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Mapped the E2 partners of MUL1 and an LIR motif in its RING that recruits GABARAP, providing a mechanistic link from the ligase to the autophagy machinery, and identified Omi/HtrA2 as a protease that turns MUL1 over.\",\n      \"evidence\": \"Modified yeast two-hybrid (RING-E2 fusions), Co-IP, LIR mutagenesis; in vitro protease assay in mnd2 mouse tissues\",\n      \"pmids\": [\"25224329\", \"24709290\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"E2 selectivity for ubiquitin vs SUMO outputs unclear\", \"GABARAP-dependent mitophagy substrate cargo not defined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Connected MUL1-dependent DRP1 SUMOylation to ER–mitochondrial contact-site stabilization required for cytochrome c release, positioning MUL1 downstream of BAX/BAK in apoptosis.\",\n      \"evidence\": \"Loss-of-function, SUMOylation and contact-site imaging, calcium flux and cytochrome c release assays, BAX/BAK epistasis\",\n      \"pmids\": [\"26384664\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of contact-site stabilization by SUMO-DRP1 not resolved\", \"Link to upstream apoptotic triggers incomplete\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showed MUL1 ubiquitinates ULK1 upon its mitochondrial translocation, integrating MUL1 into ATG5/ULK1-dependent stress-induced mitophagy.\",\n      \"evidence\": \"Co-IP, ubiquitination assays, genetic dependency on ATG5/ULK1, mitophagy assays\",\n      \"pmids\": [\"26018823\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ubiquitin chain type and consequence on ULK1 not defined here\", \"Selectivity of ULK1 targeting unclear\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Established functional redundancy between MUL1 and Parkin in developmental mitophagy, eliminating paternal mitochondria via a PINK1/FIS1/P62-dependent route.\",\n      \"evidence\": \"Genetic knockout in mouse embryos and fibroblasts, double-mutant analysis, mitophagy imaging\",\n      \"pmids\": [\"27852436\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether MUL1 acts via ubiquitin or SUMO output here untested\", \"Substrate driving paternal mitochondrial clearance unidentified\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Resolved MUL1's antiviral role as a positive one, showing MAPL-dependent RIG-I SUMOylation is required upstream of RIG-I activation for antiviral transcription.\",\n      \"evidence\": \"BioID interactome during Sendai infection, in vivo/in vitro KO, RIG-I SUMOylation assay, epistasis with constitutively active RIG-I\",\n      \"pmids\": [\"28273895\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Reconciliation with earlier inhibitory RIG-I report not addressed\", \"RIG-I SUMO-acceptor sites not mapped\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Determined the RING domain solution structure and mapped its direct interaction with the p53 transactivation domain, giving the first atomic view of substrate engagement.\",\n      \"evidence\": \"NMR structure determination and chemical-shift perturbation, in vitro binding\",\n      \"pmids\": [\"31235254\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of p53-TAD ubiquitination on p53 activity not shown\", \"Cellular context of p53 targeting undefined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined MUL1 as an ER–mitochondria tethering antagonist whose loss drives a biphasic hyperfusion-then-calcineurin/DRP1-fragmentation/Parkin-mitophagy response, linking the ligase to calcium homeostasis.\",\n      \"evidence\": \"Neuronal KO, Ca2+ flux, calcineurin inhibition, contact-site imaging, Mfn2/PTPIP51 epistasis and rescue\",\n      \"pmids\": [\"31409786\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct substrate at the tether unresolved\", \"How a single ligase produces opposing temporal phases not fully mechanistic\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Provided the mechanistic basis for MUL1 ubiquitinating intrinsically disordered substrates, showing the RING recruits p53-TAD together with UBE2D2~Ub and induces a closed, transfer-competent E2 conformation.\",\n      \"evidence\": \"Crystal/NMR of RING:UBE2D2, ubiquitin oxyester mimetics, hydrolysis assays, UBE2D2 N77A mutagenesis, affinity measurements\",\n      \"pmids\": [\"35048531\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In-cell p53 regulation by this mechanism not demonstrated\", \"Generalizability to other disordered substrates untested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established MUL1 as a metabolic gatekeeper through K48 degradation of Akt2 and HIF-1α (and via UBXN7), restraining the shift from oxidative phosphorylation to glycolysis and lipid remodeling.\",\n      \"evidence\": \"KO cells, metabolomics/lipidomics, Seahorse flux, substrate KO and chemical modulators; UBXN7 substrate identification with K48 assays\",\n      \"pmids\": [\"35846359\", \"32005965\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Hierarchy among Akt2/HIF-1α/UBXN7 outputs unclear\", \"Tissue-specific metabolic relevance not fully mapped\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Extended MUL1 substrate range beyond mitochondria, identifying SUMOylation of the peroxisomal transporter ABCD3 as a cell-autonomous regulator of hepatic bile-acid synthesis in viable KO mice.\",\n      \"evidence\": \"KO mice, BioID interactome, SUMO conjugation assays, bile-acid measurement, primary hepatocytes\",\n      \"pmids\": [\"37962001\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which ABCD3 SUMOylation alters transport not defined\", \"Cross-organelle access of a mitochondrial ligase to peroxisomal substrate unexplained\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Demonstrated MUL1 SUMOylates HSPA9 to drive its nuclear export and downstream SUZ12/EZH2 degradation, coupling MUL1 to chromatin-modifier turnover and tumor suppression; also showed DRP1 SUMOylation drives mitochondrial dysfunction in septic cardiomyocytes and ROS/DDR control in oocytes.\",\n      \"evidence\": \"SUMO assays with site mutagenesis, nuclear fractionation, ubiquitination assays, xenografts; cardiomyocyte- and germline-specific KO mice with functional readouts and NAC rescue\",\n      \"pmids\": [\"39113711\", \"39529130\", \"38639871\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How nuclear-exported HSPA9 acquires ubiquitin-targeting of SUZ12/EZH2 mechanistically unclear\", \"Single-lab models for each disease context\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identified MUL1 as an inducer of pyroptosis via MDV-mediated mtDNA trafficking to lysosomes and cGAS–gasdermin activation, embedding the ligase in an inflammatory cell-death and Parkinson's-gene (VPS35/LRRK2) network.\",\n      \"evidence\": \"Genome-wide screen, MAPL gain/loss, mtDNA trafficking and lysosomal permeabilization assays, cGAS epistasis, primary macrophages\",\n      \"pmids\": [\"41083601\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Enzymatic output (ubiquitin vs SUMO) driving MDV trafficking unresolved\", \"Direct substrate controlling mtDNA packaging unidentified\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Expanded MUL1 mitophagy/fission control with FUNDC1 ubiquitination, CPT2 degradation (enhanced by SLC44A2) restraining fatty-acid oxidation, and DRP1 SUMO1-driven fission in nucleus pulposus cells opposed by SENP5.\",\n      \"evidence\": \"Co-IP, ubiquitination/SUMOylation assays, site mutagenesis, FAO assays, AAV in vivo models, xenografts\",\n      \"pmids\": [\"41697489\", \"40592838\", \"40796734\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Context-specific selection among many substrates unresolved\", \"Single-lab cancer/disease models for each finding\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How MUL1 selects between ubiquitin and SUMO outputs, and which E2/E3 cofactors and signals route it to specific substrates across mitochondria, peroxisomes, and the nucleus, remains the central open question.\",\n      \"evidence\": \"Not yet addressed in the available corpus\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No unifying model for ubiquitin-vs-SUMO substrate choice\", \"Regulation of MUL1 access to non-mitochondrial substrates undefined\", \"PINK1 SUMOylation control of basal mitophagy rests on a preprint only\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 2, 6, 15, 19, 22, 23]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 2, 6, 17, 21, 22]},\n      {\"term_id\": \"GO:0016874\", \"supporting_discovery_ids\": [0, 6, 15, 19]},\n      {\"term_id\": \"GO:0031386\", \"supporting_discovery_ids\": [2, 10, 13, 23, 30]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [0, 2, 10, 16, 28]},\n      {\"term_id\": \"GO:0005741\", \"supporting_discovery_ids\": [0, 18]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [7, 11, 12, 18]},\n      {\"term_id\": \"R-HSA-1852241\", \"supporting_discovery_ids\": [0, 2, 10, 16]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [1, 10, 28]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [19, 22, 23, 27]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [13, 28]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [6, 15, 19, 22]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"DRP1\", \"AKT\", \"HIF1A\", \"ULK1\", \"PINK1\", \"TRAF2\", \"MAVS\", \"ABCD3\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}